United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

25 Apr 2017
Change (% chg)

¥16 (+0.30%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Takeda Pharmaceutical says splitting off partial Takeda Development Center Japan businesses to unit and plans JV with PRA Health Sciences
Friday, 7 Apr 2017 02:54am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Says it plans to transfer partial Takeda Development Center Japan business related to clinical trials, pharmacovigilance services for both development and marketed products which are operated by TDC Japan, to its wholly owned unit as succeeding company which is established on March 30 . Business split-off will be effective on June 1 . Says co will sell 50 percent stake of shares in the unit (the succeeding company) to PRA Health Sciences Inc's unit Pharm Research Associates (UK) Ltd (PRA(UK)), at an undisclosed price, on June 1 .Through the transaction, the succeeding company will become a joint venture between Takeda and PRA(UK).  Full Article

Finch Therapeutics, Takeda collaborate to develop microbiome therapeutics in inflammatory bowel disease
Wednesday, 5 Apr 2017 07:20am EDT 

Takeda Pharmaceutical Co Ltd <4502.T> : Finch Therapeutics and Takeda announce global collaboration to develop microbiome therapeutics in inflammatory bowel disease (ibd) . Takeda Pharmaceutical Co Ltd says under terms of agreement, Takeda will make an upfront payment of $10 million to Finch . Takeda Pharmaceutical Co Ltd says further details of agreement were not disclosed .Takeda Pharmaceutical - Finch will be eligible for development, regulatory, commercial financial milestones & tiered royalties on worldwide net sales.  Full Article

Fujifilm Holdings says outcome of ToB offered by unit for shares in Wako Pure Chemical Industries Ltd
Tuesday, 4 Apr 2017 03:08am EDT 

Fujifilm Holdings Corp <4901.T> : Says 16.8 million shares of Wako Pure Chemical Industries Ltd were offered in a takeover bid by co's wholly owned unit from Feb. 27 to April 3 . Acquisition price at 8,535 yen per share . Settlement date starts from April 21 .Co's unit will own 93.50 percent stake (19,994 voting rights) in Wako Pure Chemical Industries Ltd, up from 14.82 percent stake (3,170 voting rights), after transaction.  Full Article

Takeda Pharmaceutical forms drug development company with two partners - Nikkei
Tuesday, 14 Mar 2017 03:40pm EDT 

Nikkei: Takeda pharmaceutical formed 10 billion yen ($87.2 million) drug development company with two partners .Takeda pharma owns 19.5% stake & public-private innovation network corp of japan holds 70.5% stake in scohia pharma, while medipal holds 10%.  Full Article

R&I removes Takeda Pharmaceutical from rating monitor and downgrades rating to "AA-" – R&I
Wednesday, 1 Mar 2017 01:33am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Rating and Investment Information, Inc. (R&I) removed the co from rating monitor - R&I . R&I downgraded its rating to "AA-" from "AA" - R&I .Rating outlook stable - R&I.  Full Article

Fujifilm Holdings offers ToB for 18.2 mln shares of Wako Pure Chemical Industries, Ltd.
Friday, 24 Feb 2017 01:18am EST 

Fujifilm Holdings Corp <4901.T>: Says the co offered a takeover bid for 18.2 million shares (or no less than 12.5 million shares) of Wako Pure Chemical Industries, Ltd., aiming to fully acquire it . Says offered purchase price at 8,535 yen per share . Takeover bid total amount at 155.47 billion yen . Offering period from Feb. 27 to April 3 .Settlement starts on April 21.  Full Article

Takeda Pharmaceutical to transfer consumer healthcare business to wholly owned unit
Monday, 20 Feb 2017 02:10am EST 

Takeda Pharmaceutical Co Ltd <4502.T>: Says the co plans to transfer domestic consumer healthcare business to its wholly owned unit, a Tokyo-based medical supplies firm .Says effective April 1.  Full Article

TiGenix and Takeda report new data on Cx601
Friday, 17 Feb 2017 03:01am EST 

TiGenix NV :TiGenix and Takeda <4502.T> report on Friday morning new data highlighting maintenance of long-term remission of complex perianal fistulas in Crohn's disease patients with Cx601.  Full Article

Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals
Friday, 17 Feb 2017 02:01am EST 

Takeda Pharmaceutical Co Ltd <4502.T> :Says co completes full acquisition of ARIAD Pharmaceuticals Inc on Feb. 16(U.S. local time), at $24.00 per share.  Full Article

Takeda Pharmaceutical & Ovid Therapeutics announces clinical development,commercialization collaboration for TAK-935
Wednesday, 18 Jan 2017 07:03am EST 

Takeda Pharmaceutical Co Ltd: Takeda and Ovid Therapeutics announce innovative clinical development, commercialization collaboration for TAK-935 in rare pediatric epilepsies . Takeda Pharmaceutical says received equity in Ovid and may be eligible to receive certain milestone payments based on the advancement of TAK-935 . Takeda Pharmaceutical says Takeda will lead commercialization in Japan, and has the option to lead in asia and other selected geographies . Takeda Pharmaceutical says Cos to share in development and commercialization costs on 50/50 basis; if successful, will share in profits on 50/50 basis . Takeda Pharmaceutical says if mutually agreed, additional orphan central nervous system indications may also be pursued . Takeda Pharmaceutical says Ovid will lead clinical development activities and commercialization of TAK-935 in the U.S., Europe, Canada and Israel . Takeda pharmaceutical says additional financial details were not disclosed .Takeda pharmaceutical says companies expect to initiate a phase 1B/2A study in 2017 in patients with rare epileptic encephalopathies.  Full Article

More From Around the Web

Deals of the day-Mergers and acquisitions

April 25 The following bids, mergers, acquisitions and disposals were reported by 1300 GMT on Tuesday: ** Tyson Foods Inc, the No. 1 U.S. meat processor, said it would buy packaged sandwich supplier AdvancePierre Foods Holdings Inc for about $3.2 billion in cash, to expand its fast-growing portfolio of prepared foods. ** Straight Path Communications Inc said it received a $104.64 per-share all-stock buyout offer from a "multi-national telecommunications company", topping AT&T Inc's o